Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 22Thoracic 7Gastrointestinal 5Tumor-Agnostic 4Lymphoid 4Genitourinary 4CNS 4Head & Neck 3Dermatologic 3Sarcoma 2Gynecologic 2Plasma cell 1Other solid neoplasm 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6Nivolumab 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × abemaciclib × Endocrine × Clear all
NCT04552769 2025-06-05

Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Stanford University

Phase 2 Completed
9 enrolled 10 charts
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡